Showing 2461-2470 of 5909 results for "".
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Diseasehttps://modernod.com/news/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease/2481159/Ocuphire Pharma announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11 am to 12:30 pm Eastern Time. The event will
- SpyGlass Pharma Presents 3-Month Data from the First-In-Human Trial of Its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/SpyGlass Pharma announced 3-month data from a first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform lowered IOP in patients with open-angle glaucoma or ocular hypertension. The data were showcased during an oral presentation at the Eyecelerator inn
- Trefoil Therapeutics Announces Positive Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgeryhttps://modernod.com/news/trefoil-therapeutics-announces-positive-phase-2-study-data-showing-corneal-regeneration-and-vision-recovery-following-descemet-stripping-only-dso-surgery/2481137/Trefoil Therapeutics announced positive phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary engineered fibroblast growth factor-1 (FGF1) variant, is delivered as an intracameral injection into the anterior chamber of the eye. Most
- Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitishttps://modernod.com/news/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify-and-diagnose-demodex-blepharitis/2481133/Tarsus Pharmaceuticals announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage ey
- Johnson & Johnson Vision Expands Access to Myopia Management for More Patients With Abiliti Overnight Lenseshttps://modernod.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters (previously 4.00 diopters). Johnson & Johnson Vision also announced greater availability of the lenses nationwi
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,
- Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoptionhttps://modernod.com/news/neurolens-raises-67-million-investment-to-develop-new-products-and-accelerate-adoption/2481080/Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wac